Fig. 3From: Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutationTTP (A) and OS (B) curves of EGFR/TP53 co-mutation patients receiving EGFR-TKI monotherapy (T) or EGFR-TKIs combined with chemotherapy (TC). TTP (C) and OS (D) curves of EGFR/TP53 co-mutation patients without brain metastases receiving T or TCBack to article page